Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.
GRPR
PSMA
bispecific heterodimers
prostate cancer
radio-iodine
theranostics
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
23 Jul 2019
23 Jul 2019
Historique:
received:
15
06
2019
revised:
16
07
2019
accepted:
20
07
2019
entrez:
26
7
2019
pubmed:
26
7
2019
medline:
26
7
2019
Statut:
epublish
Résumé
Gastrin-releasing peptide receptor (GRPR) and prostate-specific membrane antigen (PSMA) are overexpressed in most prostate cancers. GRPR expression is higher in early stages while PSMA expression increases with progression. The possibility of targeting both markers with a single theranostics radiotracer could improve patient management. Three GRPR/PSMA-targeting bispecific heterodimers (urea derivative PSMA-617 and bombesin-based antagonist RM26 linked via X-triazolyl-Tyr-PEG2, X = PEG2 (BO530), (CH
Identifiants
pubmed: 31340483
pii: pharmaceutics11070358
doi: 10.3390/pharmaceutics11070358
pmc: PMC6680768
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cancerfonden
ID : 2017/425
Organisme : Cancerfonden
ID : CAN2015/350
Organisme : Vetenskapsrådet
ID : 2015-02509
Organisme : Cancerfonden
ID : CAN 2018/436
Organisme : Vetenskapsrådet
ID : 2015-02353
Références
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
N Engl J Med. 2018 Feb 15;378(7):645-657
pubmed: 29412780
J Nucl Med. 2006 Mar;47(3):492-501
pubmed: 16513619
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Nucl Med Biol. 2014 Apr;41(4):355-63
pubmed: 24508213
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92
pubmed: 24577951
Nucl Med Biol. 2000 Nov;27(8):827-35
pubmed: 11150717
Int J Pept Protein Res. 1990 Mar;35(3):161-214
pubmed: 2191922
Prostate. 2014 May;74(6):659-68
pubmed: 24464532
Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):623-32
pubmed: 21170526
Prostate. 2014 Feb;74(2):210-6
pubmed: 24132735
J Org Chem. 2002 May 3;67(9):3057-64
pubmed: 11975567
Lancet. 2016 Jan 2;387(10013):70-82
pubmed: 26074382
Front Neuroendocrinol. 2001 Oct;22(4):248-91
pubmed: 11587553
J Nucl Med. 2007 Jan;48(1):88-93
pubmed: 17204703
Anal Biochem. 1981 Oct;117(1):136-46
pubmed: 7316186
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Food Chem Toxicol. 1992 Sep;30(9):795-801
pubmed: 1427518
J Biol Chem. 1990 Jul 15;265(20):12052-8
pubmed: 2164025
J Nucl Med. 2018 Dec 20;:
pubmed: 30573642
Prostate. 2014 Feb;74(2):217-24
pubmed: 24150752
Contrast Media Mol Imaging. 2017 Aug 10;2017:6873684
pubmed: 29097932
Biomed Eng Comput Biol. 2016 Mar 02;7(Suppl 1):1-15
pubmed: 26966397
Clin Cancer Res. 2002 Apr;8(4):1139-46
pubmed: 11948125
Bioconjug Chem. 2016 Mar 16;27(3):737-51
pubmed: 26726823
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670
pubmed: 28624848
Prostate. 2000 Mar 1;42(4):295-303
pubmed: 10679759
J Pept Res. 1999 Mar;53(3):275-83
pubmed: 10231715
J Org Chem. 2001 Dec 14;66(25):8454-62
pubmed: 11735525
Cancer Res. 1999 Jul 1;59(13):3192-8
pubmed: 10397265
Angew Chem Int Ed Engl. 2002 Jul 15;41(14):2596-9
pubmed: 12203546
Eur Urol. 2014 Feb;65(2):467-79
pubmed: 24321502
Nucl Med Commun. 2019 Mar;40(3):278-286
pubmed: 30763290
Med Res Rev. 2019 Jan;39(1):40-69
pubmed: 29771460
Urol Oncol. 1995 Jan-Feb;1(1):18-28
pubmed: 21224086
J Nucl Med. 2016 Apr;57(4):557-62
pubmed: 26659347
Int J Cancer. 1998 Feb 20;79(1):82-90
pubmed: 9495364
Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330
pubmed: 31099673
Int J Cancer. 2019 Dec 15;145(12):3347-3358
pubmed: 31077356
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
J Control Release. 2014 Aug 10;187:118-32
pubmed: 24878184
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Ann Oncol. 2007 Sep;18(9):1457-66
pubmed: 17351255
Bioconjug Chem. 2013 Jul 17;24(7):1144-53
pubmed: 23763444
J Org Chem. 2016 Apr 15;81(8):3443-6
pubmed: 26998999
J Nucl Med. 2015 Jun;56(6):914-20
pubmed: 25883127
Urology. 1998 Oct;52(4):637-40
pubmed: 9763084